source
- Sanofi and Regeneron deepen collaboration, adding new immunology antibody programSanofi and Regeneron announced an expanded partnership that builds on the success of their joint drug Dupixet, targeting a pipeline of experimental antibodies for immunological disorders. Under th…
- Lilly ends partnership with Foghorn after lead cancer drug fails efficacy testsLilly announced it is ending its collaboration with Foghorn Therapeutics after the biotech's lead cancer candidate, FHD-909, did not meet efficacy benchmarks in testing. The decision halts the join…